Egypt · Delayed Price · Currency is EGP Ibnsina Pharma Statistics
Total Valuation
Ibnsina Pharma has a market cap or net worth of EGP 10.54 billion. The enterprise value is 36.24 billion.
| Market Cap | 10.54B |
| Enterprise Value | 36.24B |
Important Dates
The last earnings date was Wednesday, February 25, 2026.
| Earnings Date | Feb 25, 2026 |
| Ex-Dividend Date | Oct 13, 2025 |
Share Statistics
Ibnsina Pharma has 1.01 billion shares outstanding.
| Current Share Class | 1.01B |
| Shares Outstanding | 1.01B |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 26.01% |
| Owned by Institutions (%) | 24.14% |
| Float | 652.98M |
Valuation Ratios
The trailing PE ratio is 13.67 and the forward PE ratio is 7.69.
| PE Ratio | 13.67 |
| Forward PE | 7.69 |
| PS Ratio | 0.14 |
| PB Ratio | 3.79 |
| P/TBV Ratio | 4.14 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 9.38, with an EV/FCF ratio of -44.98.
| EV / Earnings | 47.00 |
| EV / Sales | 0.47 |
| EV / EBITDA | 9.38 |
| EV / EBIT | 10.23 |
| EV / FCF | -44.98 |
Financial Position
The company has a current ratio of 1.03, with a Debt / Equity ratio of 9.58.
| Current Ratio | 1.03 |
| Quick Ratio | 0.71 |
| Debt / Equity | 9.58 |
| Debt / EBITDA | 6.91 |
| Debt / FCF | -33.11 |
| Interest Coverage | 1.38 |
Financial Efficiency
Return on equity (ROE) is 39.54% and return on invested capital (ROIC) is 11.47%.
| Return on Equity (ROE) | 39.54% |
| Return on Assets (ROA) | 6.83% |
| Return on Invested Capital (ROIC) | 11.47% |
| Return on Capital Employed (ROCE) | 79.04% |
| Weighted Average Cost of Capital (WACC) | 8.16% |
| Revenue Per Employee | 13.93M |
| Profits Per Employee | 140,201 |
| Employee Count | 5,500 |
| Asset Turnover | 2.36 |
| Inventory Turnover | 9.47 |
Taxes
In the past 12 months, Ibnsina Pharma has paid 125.36 million in taxes.
| Income Tax | 125.36M |
| Effective Tax Rate | 11.64% |
Stock Price Statistics
The stock price has increased by +43.29% in the last 52 weeks. The beta is 0.57, so Ibnsina Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.57 |
| 52-Week Price Change | +43.29% |
| 50-Day Moving Average | 11.43 |
| 200-Day Moving Average | 10.72 |
| Relative Strength Index (RSI) | 37.31 |
| Average Volume (20 Days) | 8,069,196 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Ibnsina Pharma had revenue of EGP 76.60 billion and earned 771.11 million in profits. Earnings per share was 0.76.
| Revenue | 76.60B |
| Gross Profit | 6.45B |
| Operating Income | 3.54B |
| Pretax Income | 1.08B |
| Net Income | 771.11M |
| EBITDA | 3.71B |
| EBIT | 3.54B |
| Earnings Per Share (EPS) | 0.76 |
Balance Sheet
The company has 975.19 million in cash and 26.67 billion in debt, with a net cash position of -25.70 billion or -25.49 per share.
| Cash & Cash Equivalents | 975.19M |
| Total Debt | 26.67B |
| Net Cash | -25.70B |
| Net Cash Per Share | -25.49 |
| Equity (Book Value) | 2.78B |
| Book Value Per Share | 2.76 |
| Working Capital | 794.75M |
Cash Flow
In the last 12 months, operating cash flow was -71.06 million and capital expenditures -734.60 million, giving a free cash flow of -805.66 million.
| Operating Cash Flow | -71.06M |
| Capital Expenditures | -734.60M |
| Free Cash Flow | -805.66M |
| FCF Per Share | -0.80 |
Margins
Gross margin is 8.42%, with operating and profit margins of 4.62% and 1.24%.
| Gross Margin | 8.42% |
| Operating Margin | 4.62% |
| Pretax Margin | 1.41% |
| Profit Margin | 1.24% |
| EBITDA Margin | 4.85% |
| EBIT Margin | 4.62% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 0.16, which amounts to a dividend yield of 1.52%.
| Dividend Per Share | 0.16 |
| Dividend Yield | 1.52% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | 4 |
| Payout Ratio | 21.12% |
| Buyback Yield | n/a |
| Shareholder Yield | 1.52% |
| Earnings Yield | 7.31% |
| FCF Yield | -7.64% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on June 1, 2022. It was a forward split with a ratio of 1.16666.
| Last Split Date | Jun 1, 2022 |
| Split Type | Forward |
| Split Ratio | 1.16666 |
Scores
Ibnsina Pharma has an Altman Z-Score of 2.73 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.73 |
| Piotroski F-Score | 4 |